Please note that some translations using Google Translate may not be accurately represented, and image captions and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result for using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Patients have the opportunity to participate in trials for new therapies for all phases of Chronic Lymphocytic Leukemia (CLL), including advanced CLL. These trials include:
Learn more about clinical trials for CLL patients.
Translational science, which quickly moves laboratory findings into clinical practice, is also a key focus of the Center for Chronic Lymphocytic Leukemia. This includes:
Dana-Farber is currently enrolling participants for a Genetic Study of Familial Chronic Lymphocytic Lymphoma. This study, led by Jennifer R. Brown, MD, PhD, seeks to identify the genes that cause the disease, in order to develop methods of prevention and diagnosis counseling. To be eligible, participants must have at least two first-degree relatives (e.g., parent, sibling, or child) who have a lymphoma or lymphoproliferative disorder. For more information, including detailed eligibility guidelines and participation requirements, contact lead investigator Jennifer R Brown, MD, PhD or study coordinator Alexander Vartanov.
Learn more about the Harvard Study of Genetic Factors that Lead to Lymphoma
CLL Research NewsCatherine Wu, MD, comments on her latest research on CLL, including the impact of mutated SF3B1 on CLL-associated pathways.
Appointments and Second Opinions
Matthew Davids, MD, MMSc, on Advances in CLL TreatmentMatthew Davids, MD, MMSc, of Dana-Farber’s Center for Chronic Lymphocytic Leukemia, shares updates on advances in treating newly-diagnosed and relapsed CLL. New approaches include ibrutinib + FCR for younger, newly-diagnosed patients and a combination of rituximab and venetoclax for relapsed patients.